<DOC>
	<DOCNO>NCT00953706</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy ivacaftor participant cystic fibrosis ( CF ) age 12 year older homozygous F508del-CF transmembrane conductance regulator ( CFTR ) mutation . Ivacaftor potent selective CFTR potentiator wild-type , G551D , F508del , R117H form human CFTR protein . Potentiators pharmacological agent increase chloride ion transport property channel presence cyclic adenosine monophosphate ( AMP ) -dependent protein kinase A ( PKA ) activation .</brief_summary>
	<brief_title>Study Ivacaftor Cystic Fibrosis Subjects Aged 12 Years Older Homozygous F508del-CFTR Mutation</brief_title>
	<detailed_description>This study investigate effect ivacaftor participant cystic fibrosis ( CF ) &gt; =12 year age force expiratory volume 1 second ( FEV1 ) &gt; =40 percent ( % ) predict . This study conduct 2 part . - Part A study randomize , double-blind , placebo-controlled , parallel-group evaluation participant CF age 12 year older homozygous F508del-CFTR mutation . - Part B study open-label extension Part A , enrol participant complete Part A meet pre-specified endpoint criterion , explore safety efficacy ivacaftor long-term treatment participant CF age 12 year older homozygous F508del-CFTR mutation .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Confirmed diagnosis cystic fibrosis ( CF ) homozygous F508delCFTR mutation Forced expiratory volume 1 second ( FEV1 ) least 40 % predict normal age , gender , height Willing use least 2 highly effective birth control method study No clinically significant abnormality would interfere study assessment , judge investigator Able understand comply protocol requirement , restriction , instruction likely complete study plan , judge investigator History illness condition might confound result study pose additional risk administer study drug subject Acute respiratory infection , pulmonary exacerbation , change therapy pulmonary disease within 4 week Day 1 study History alcohol , medication illicit drug abuse within one year prior Day 1 Abnormal liver function &gt; =3 x upper limit normal Abnormal renal function Screening History solid organ hematological transplantation Pregnant breastfeeding ( woman ) Ongoing participation another therapeutic clinical study prior participation investigational drug study within 30 day prior screen Previous participation VX809 study Used inhale hypertonic saline treatment Concomitant use inhibitor inducer cytochrome P450 3A4 ( CYP3A4 )</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Fibrosis</keyword>
	<keyword>Pancreatic Diseases</keyword>
	<keyword>Digestive System Diseases</keyword>
	<keyword>Lung Diseases</keyword>
	<keyword>Respiratory Tract Diseases</keyword>
	<keyword>Genetic Diseases , Inborn</keyword>
	<keyword>Infant , Newborn , Diseases</keyword>
	<keyword>Pathologic Processes</keyword>
</DOC>